SMTL ID : 9cdx.1

Crystal structure of DLK with inhibitor bound

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.38 Å

Oligo State

monomer

Ligands

1 x 01: (5P)-5-[(4R)-6-(propan-2-yl)imidazo[1,5-a]pyridin-1-yl]-3-(trifluoromethyl)pyridin-2-amine

01.1: 17 residues within 4Å: Chain A: V.20, G.21, Q.25, V.28, A.39, K.41, I.63, M.79, E.80, F.81, C.82, A.83, Q.84, G.85, Q.86, L.132, S.142 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:V.28, A:F.81, A:L.132, A:L.132 Hydrogen bonds: A:E.80, A:C.82 Halogen bonds: A:S.142

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Lagiakos, H.R. et al., In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury. J.Med.Chem. (2024)

Release Date

2025-02-19

Peptides

Mitogen-activated protein kinase kinase kinase 12: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Mitogen-activated protein kinase kinase kinase 12

Related Entries With Identical Sequence